問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Emergency Medicine

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of General Internal Medicine

National Taiwan University Cancer Center

Division of General Internal Medicine

更新時間：2025-09-23

何肇基CHAO-CHI HO, CHAO-CHI HO
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

225Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

何肇基

List

378Cases

2013-12-23 - 2021-08-12

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2021-11-01 - 2027-03-20

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-03-25 - 2025-10-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2018-06-01 - 2022-09-30

Phase III

RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy

  • Condition/Disease

    Small cell lung cancer

  • Test Drug

    ONIVYDE

Participate Sites
5Sites

Recruiting5Sites

劉劍英
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2013-09-01 - 2020-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2014-08-01 - 2021-11-19

Phase III

A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    MEDI4736

Participate Sites
6Sites

Terminated6Sites

2014-05-01 - 2023-09-30

Phase II

A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC)

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    MEDI4736

Participate Sites
5Sites

Terminated5Sites

2014-10-15 - 2016-05-16

Phase I

A Phase I, Open-Label, Non-Randomised，Multicentre Study to Assess the Effect of AZD9291 on the Pharmacokinetics of Simvastatin (a Sensitive CYP3A4 Substrate) in Patients with EGFRm Positive NSCLC Whose Disease has Progressed on an EGFR TKI

  • Condition/Disease

    NSCLC

  • Test Drug

    AZD9291

Participate Sites
2Sites

Terminated2Sites

2014-08-30 - 2023-03-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2014-12-04 - 2015-07-09

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 30 31 32 33 34 38
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB